Scott Ernst
Overview
Explore the profile of Scott Ernst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
607
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mackenzie C, Deluce J, Black M, Churchman E, Winquist E, Ernst S, et al.
Curr Oncol
. 2024 Nov;
31(11):6475-6487.
PMID: 39590111
Radium-223 dichloride (radium-223) is a bone-targeting radioisotope therapy that aids in the survival of patients with metastatic castration-resistant prostate cancer (mCRPC) to bones. This study aimed to describe the clinical...
2.
Strum S, Climans S, Purcell V, Black M, Winquist E, Ernst S
J Cutan Med Surg
. 2024 Jul;
28(5):453-457.
PMID: 39056376
Background: Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer in Canada. However, few real-world reports exist on the treatment of refractory locally advanced (LA) and...
3.
Routy B, Lenehan J, Miller Jr W, Jamal R, Messaoudene M, Daisley B, et al.
Nat Med
. 2023 Nov;
30(2):604.
PMID: 37923839
No abstract available.
4.
Routy B, Lenehan J, Miller Jr W, Jamal R, Messaoudene M, Daisley B, et al.
Nat Med
. 2023 Jul;
29(8):2121-2132.
PMID: 37414899
Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has...
5.
Kartolo A, Deluce J, Hopman W, Liu L, Baetz T, Ernst S, et al.
Curr Oncol
. 2022 Mar;
29(3):1501-1513.
PMID: 35323326
Aim: To evaluate optimal systemic therapy sequencing (first-line targeted therapy (1L-TT) vs. first-line immunotherapy (1L-IO)) in patients with BRAF-mutated metastatic melanoma. Methods: Nation-wide prospective data of patients with newly diagnosed...
6.
Tong J, Mitchell B, Roth K, Logan D, Ernst S
J Cutan Med Surg
. 2021 Oct;
26(2):143-148.
PMID: 34663118
Background: Vismodegib is a novel Hedgehog pathway inhibitor that has revolutionized the treatment of patients with advanced basal cell carcinoma (BCC) who are poor candidates for surgery or radiation. Few...
7.
Clemons M, Liu M, Stober C, Pond G, Alzahrani M, Ong M, et al.
J Bone Oncol
. 2021 Sep;
30:100388.
PMID: 34567960
Background: We present the 2-year results of a randomised trial comparing 4- versus 12-weekly bone-targeting agents (BTAs) in patients with bone metastases from breast or castration-resistant prostate cancer (CRPC). Patients...
8.
Lavi A, Winquist E, Nair S, Chin J, Izawa J, Fernandes R, et al.
Curr Oncol
. 2021 Mar;
28(1):78-85.
PMID: 33704177
Extragonadal germ cell tumors account for 2-5.7% of germ cell tumors (GCTs). Of these, primary mediastinal GCTs (PMGCTs) are responsible for 16-36% of cases. Given the rarity of these tumors,...
9.
Hodi F, Chapman P, Sznol M, Lao C, Gonzalez R, Smylie M, et al.
Melanoma Res
. 2020 Nov;
31(1):67-75.
PMID: 33234846
CheckMate 218, a North American expanded access program (EAP), investigated nivolumab plus ipilimumab in patients with advanced melanoma. Safety and efficacy, including 2-year survival in clinically relevant patient subgroups, are...
10.
Clemons M, Ong M, Stober C, Ernst S, Booth C, Canil C, et al.
Eur J Cancer
. 2020 Oct;
142:132-140.
PMID: 33023785
Background: Optimal dosing of bone-targeted agents (BTAs), in patients with bone metastases remains an important clinical question. This trial compared 4-weekly versus 12-weekly therapy. Patients And Methods: Patients with bone...